VALPROIC ACID Drug Patent Profile
✉ Email this page to a colleague
When do Valproic Acid patents expire, and when can generic versions of Valproic Acid launch?
Valproic Acid is a drug marketed by Bionpharma, Catalent, Eywa, Par Pharm, Scherer Rp, Sun Pharm Inds Ltd, Upsher Smith Labs, Ani Pharms, Chartwell Rx, Hikma, Lannett Co Inc, Nostrum Labs Inc, Pharm Assoc, Pharmobedient Cnsltg, and Quagen. and is included in fifteen NDAs.
The generic ingredient in VALPROIC ACID is valproic acid. There are seventeen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the valproic acid profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Valproic Acid
A generic version of VALPROIC ACID was approved as valproic acid by CATALENT on October 29th, 1991.
Summary for VALPROIC ACID
US Patents: | 0 |
Applicants: | 15 |
NDAs: | 15 |
Finished Product Suppliers / Packagers: | 15 |
Raw Ingredient (Bulk) Api Vendors: | 144 |
Clinical Trials: | 189 |
Patent Applications: | 4,377 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VALPROIC ACID |
DailyMed Link: | VALPROIC ACID at DailyMed |
Recent Clinical Trials for VALPROIC ACID
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sohag University | Phase 2/Phase 3 |
Dr Cipto Mangunkusumo General Hospital | Phase 4 |
Wayne State University | Phase 4 |
Pharmacology for VALPROIC ACID
Drug Class | Anti-epileptic Agent Mood Stabilizer |
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |